Does an above-range serum neural-receptor IgG/IgA result prove pathogenic antibodies or CNS access?

A serum neural-receptor IgG/IgA result above an assay’s reference range is an analytical finding, not a diagnosis. In a 77-year-old man—as at any age—its clinical meaning depends on the antibody target, isotype, titre, assay method, neurological syndrome, and objective corroboration.

What the result shows

• An above-range result indicates assay-detectable reactivity consistent with antibody binding to that test’s specified target. Cell-based assays can present cell-surface antigens in relatively native conformations, but this demonstrates binding under assay conditions, not necessarily binding to receptors in vivo.
• Background or cross-reactive signals and false-positive serum results occur; neuronal-antibody positivity has been reported in healthy controls at a mean frequency of 0.23% with standard assays. IgG has established relevance for many neural-surface antibody disorders, whereas IgA is not broadly validated diagnostically across targets.

Pathogenicity and CNS access

• Serum positivity alone does not establish autoimmune encephalitis or prove that antibodies cause symptoms. Diagnosis requires a compatible subacute syndrome plus supportive findings—such as seizures, focal deficits, inflammatory CSF, suggestive MRI—and exclusion of alternatives.
• Pathogenicity requires target- and epitope-specific functional evidence, for example receptor cross-linking/internalization, receptor blockade, disrupted protein interactions, or disease-relevant effects in passive-transfer experiments.
• A serum test does not show antibody in CSF, blood–brain-barrier passage, or intrathecal synthesis. Paired testing matters: CSF is particularly important for NMDAR and GFAP antibodies, while serum is often more sensitive for LGI1 and CASPR2. An antigen-specific CSF antibody index can support intrathecal synthesis, but is not diagnostic alone.

Bottom line

• The claim is well supported: the result documents assay-level serum antibody reactivity, but by itself proves neither pathogenicity, CNS access, nor autoimmune encephalitis.